MERZ-AESTHETICS
Merz Aesthetics is presenting at the 2024 International Master Course on Aging Science (IMCAS) World Congress a total of 5 abstracts highlighting the field of regenerative aesthetics and how its product portfolio is contributing. This year’s IMCAS is the 25th edition of the largest scientific aesthetics congress worldwide beginning Thursday, February 1st to Saturday, February 3.
“Merz Aesthetics is looking forward to sharing these new findings, as they provide strong scientific evidence to support the evolving field of regenerative aesthetics,” said Terri Phillips, M.D., Chief Medical Affairs Officer, Merz Aesthetics. “We take pride in the innovation of our product portfolio and how it’s helping to shape the future of the aesthetics industry.”
“Our focus in this year’s Merz Aesthetics sponsored symposium at the IMCAS Congress is the future of regenerative biostimulation with Radiesse”, said Gonzalo Mibelli, President EMEA, Merz Aesthetics. “Together with a panel of renowned industry experts we discuss the topic of skin regeneration, share insights into techniques and personalized treatment approaches aligned with our Merz Aesthetics commitment on scientific exchange and innovation.”
Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.
- Merz Aesthetics sponsored symposium “Mastering regenerative biostimulation” – Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Jani van Loghem, Dr. Bianca Viscomi, Friday, February 2, 2024, 4:00 p.m. – 6:00 p.m. CEST
- Merz Aesthetics support of IMCAS Cadaver Workshop – Anatomist Dr. Nicholas Moellhoff and Aesthetic Specialist Dr. Jonathan Kadouch, Thursday, February 1, 2024, 2:30 p.m. – 3:30 p.m. CEST
- IMCAS Product Analysis Session “Biostimulators” – Dr. Alec McCarthy, Director Regenerative Aesthetics, Merz Aesthetics, Friday, February 2, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Product Analysis Session “Toxins” – PH.D. Andy Curry, associate medical director, Merz Aesthetics, Saturday, February 3, 2024, 8:30 a.m. ‒ 10:00 a.m. CEST
- IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO Merz Aesthetics, Friday, February 2, 2024, 2:00 p.m. – 3:30 p.m. CEST
Booth Talks
- Treatment Options for Hand Rejuvenation - Dr. Elena Bagnenko, Thursday, February 1, 2024, 1:00p.m. – 1.30 p.m.
- Innovative Technique for Tear Trough Correction - Dr. Yahia Hashish, Thursday, February 1, 2024, 3:30p.m. – 4.00 p.m.
- What are THE Really Important Aspects when using CaHA as a Regenerative Biostimulator? - Dr. Gabriela Casabona, Friday, February 2, 10:00 a.m. – 10.30 a.m.
- Advancing Skin Radiance, Dr. Juan Martín Zárate González, Friday, February 2, 1:00 p.m. – 1.30 p.m.
- Combination of Treatments for Improving Skin Quality - Dr. Ana Diez Gandia, Saturday, February 3, 2024, 10:00 a.m. – 10.30 a.m.
E-Poster Presentations
Virtual posters will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts.
- A review of Radiesse as a regenerative aesthetic treatment. Presenting author: Dr. Shino Bay Aguilera. Co-Authors: Dr. Alec McCarthy, Dr. Saami Khalifian, Dr.Z. Paul Lorenc, Dr. Katherine Goldie, Dr. W. Gregory Chernoff
- The evolving field of regenerative aesthetics. Presenting author: Dr. Katherine Goldie
- Physical properties of diluted Radiesse. Presenting author: Dr. Vasanop Vachiramon. Co-authors: Dr. Chayanee Likitwattananurak, Dr. Nawara Sakpuwadol, Dr. Tanat Yongpisarn
- Attraction of fibroblasts by Micro-Focused Ultrasound (MFU-V). Presenting author: Dr. Kay Marquardt. Co-authors: Dr. F. Wegener, Dr. Nils Warfving, Dr. Christian Hartmann, Dr. Dr. Thomas Hengl
- Retrospective case series following patients treated with a combination of CPM-HA and CaHA fillers. Presenting author: Dr. Bianca Viscomi Co-authors: Dr. Yana Yutskovskaya, Dr. Heidi Waldorf, Dr. Ting Song Lim
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201288217/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nordic Firms Seek Sovereign Clouds for Compliant Modernization22.1.2026 10:00:00 CET | Press release
Enterprises reshape cloud strategies around data sovereignty, sustainability requirements and AI-native operations, ISG Provider Lens® report says The multi public cloud services market in the Nordics has entered a defining phase as enterprises shift from selective use of the cloud to comprehensive, compliance-driven and AI-native multicloud operating models, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2025 ISG Provider Lens® Multi Public Cloud Services report for the Nordics finds that cloud adoption across the region has moved beyond basic workload migration as companies embrace sovereign cloud models that guarantee jurisdictional control and encryption frameworks. This change reflects the impact of tightening EU regulatory frameworks that require data residency, transparency and responsible AI adoption in regulated industries and the public sector. As a result, e
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom